This study is led by the Department of Hepatobiliary Surgery of the First Affiliated Hospital of the University of Science and Technology of China (USTC), in close collaboration with multiple participating centers nationwide. The primary objective is to establish a standardized, large-scale clinical cohort database specifically for metastatic liver cancer. By collecting comprehensive data on patient demographics, primary tumor characteristics, systemic therapies, and local interventions, this registry aims to elucidate the clinical patterns and prognostic factors of secondary liver malignancies. This database will serve as a robust platform for conducting high-quality real-world studies and advancing evidence-based clinical research in the management of metastatic liver cancer.
Patients with histologically or radiologically confirmed metastatic liver cancer.
Age ≥ 18 years.
Patients who have voluntarily signed the informed consent form.
Patients with complete baseline clinical data.
Patients with primary liver cancer (e.g., hepatocellular carcinoma).
Patients with other malignant tumors that may interfere with the evaluation of liver metastasis.
Patients who have previously participated in other interventional clinical trials.
Patients with severe cognitive disorders or communication barriers that prevent informed consent.
This registry targets adult patients with histologically or radiologically confirmed metastatic liver cancer. The population encompasses patients undergoing various standard clinical management strategies, including surgical resection, local ablation, transarterial chemoembolization (TACE), and systemic therapies (chemotherapy, targeted therapy, or immunotherapy).
Cohort
Prospective
Standard of Care for Metastatic Liver Cancer
Procedure/SurgeryIn this observational patient registry, no specific interventional procedure is assigned by the investigators. Patients included in the database receive standard clinical management and treatments for metastatic liver cancer according to current clinical guidelines and physician's discretion. These procedures may include hepatectomy, ablation, transarterial chemoembolization (TACE), systemic chemotherapy, targeted therapy, or immunotherapy. This registry aims to evaluate the real-world effectiveness and safety of these standard interventions.
Overall Survival
The time interval from the date of initial diagnosis (or date of enrollment/surgery) to the date of death from any cause.
Progression-Free Survival
Description: The time interval from the date of enrollment (or initial treatment) to the date of the first documented disease progression (local recurrence or distant metastasis) or death from any cause, whichever occurs first.
Treatment-Related Adverse Events
The incidence and severity of postoperative complications or treatment-related adverse events, graded according to the Clavien-Dindo classification (for surgical complications) or CTCAE (Common Terminology Criteria for Adverse Events) version 5.0.
Click on the lead sponsor to view all of their trials.
